Immunovant, Inc. IMVT Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s stock-based comp?
- Immunovant, Inc. (IMVT) reported stock-based comp of $11.14M in Q1 2026.
- How has Immunovant, Inc.'s stock-based comp changed year-over-year?
- Immunovant, Inc.'s stock-based comp decreased by 4.7% year-over-year, from $11.69M to $11.14M.
- What is the long-term trend for Immunovant, Inc.'s stock-based comp?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s stock-based comp has grown at a 12.9% compound annual growth rate (CAGR), from $34.24M to $55.72M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.